Saturday 17 October 2026
Export DYN’s income statement to Excel — free account
Dyne Therapeutics, Inc.
In the quarter to June 2026, EPS fell 11.3%, free cash flow fell 39.1% and total debt rose 116.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
14.25
1.04
−6.80%
Follow DYN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
22.25 | 15.60 | 2.53 | 9.46 | 13.31 | 31.83 | 6.26 | 11.47 | — |
Net Debt/EBITDA |
2.05 | 1.86 | 0.51 | 1.37 | 2.38 | 5.97 | 1.08 | 1.00 | — |
Debt/Assets |
12.55% | 0.00% | 0.00% | 8.45% | 6.75% | 0.00% | 0.00% | 40.82% | 0.00% |
Debt/Equity |
0.15 | 0.00 | 0.00 | 0.10 | 0.08 | 0.00 | 0.00 | 0.81 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.90 | 0.92 | 0.80 | 0.91 | 0.80 | 0.78 | 0.80 | 0.87 | — |
Capex/Depreciation |
(8.97) | 1.23 | (1.28) | (1.04) | (0.99) | (1.50) | (6.08) | 0.00 | — |
Interest Coverage |
(75.61) | — | — | (58.61) | (202.19) | (148.10) | (47.68) | (1,918.00) | — |
| (55.71%) | (88.03%) | (137.31%) | (54.18%) | (42.02%) | (36.13%) | 162.64% | 52.66% | — | |
| (47.52%) | (74.14%) | (100.10%) | (45.93%) | (38.33%) | (32.15%) | (120.30%) | (116.38%) | — | |
ROIC |
(2,790.00%) | 0.00% | 0.00% | (480.77%) | (460.33%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(40.57%) | (51.00%) | (284.06%) | (69.05%) | (41.66%) | (17.48%) | (107.00%) | (63.66%) | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(3.15) | (3.13) | (3.16) | (3.02) | (2.42) | (3.31) | (5.52) | (0.09) | — |
Cash per Share |
8.65 | 6.82 | 2.06 | 4.93 | 7.40 | 23.99 | 5.99 | 0.18 | — |
Shareholders Equity per Share |
7.57 | 6.69 | 1.53 | 4.86 | 7.23 | 23.78 | 5.75 | 0.09 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
7.57 | 6.69 | 1.53 | 4.86 | 7.23 | 23.78 | 5.75 | 0.09 | — |
Free Cash Flow |
(405.13) | (294.74) | (188.89) | (156.71) | (123.18) | (47.67) | (13.48) | (4.16) | — |
Working Capital |
1,075.96 | 617.02 | 78.28 | 237.51 | 353.67 | 338.12 | 12.40 | 7.45 | — |
Capital Expenditures |
(1.92) | (2.38) | (0.73) | (3.07) | (3.62) | (1.16) | (1.65) | (0.13) | — |
Net Current Asset Value |
911.76 | 597.88 | 55.59 | 211.63 | 324.93 | 338.12 | 12.36 | 4.07 | — |
| Other line items | |||||||||
Quick Ratio |
21.94 | 15.20 | 2.41 | 9.11 | 13.11 | 31.49 | 6.21 | 11.43 | — |
Depreciation/Fixed assets |
0.01 | (0.36) | 0.12 | 0.50 | 0.78 | 0.40 | 0.18 | 0.22 | — |
Cash ROIC |
(18.15%) | (23.17%) | (88.10%) | (29.33%) | (15.92%) | (6.93%) | (47.02%) | (26.55%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7,877.92 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(3.14) | (3.11) | (3.15) | (2.96) | (2.35) | (3.23) | (4.84) | (0.09) | — |
Capex per Share |
(0.01) | (0.03) | (0.01) | (0.06) | (0.07) | (0.08) | (0.67) | 0.00 | — |
Average Payables |
7.32 | 14.75 | 14.10 | 4.65 | 3.74 | 2.35 | 0.89 | 0.89 | — |
Average Assets |
939.10 | 428.16 | 235.70 | 365.99 | 389.50 | 184.89 | 12.35 | 4.13 | — |
Average Common Equity |
800.98 | 360.57 | 171.83 | 310.28 | 355.28 | 164.49 | (9.14) | (9.14) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Columns are period end dates